Benzinga | Nov 10, 2021 07:14AM EST

BioXcel Therapeutics Q3 EPS $(0.96) Beats $(1.05) Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 10.28 percent increase over losses of $(1.07) per share from the same period last year.